Novel Research, LLC

Bellaire, Texas 77401

7 studies enrolling now · 16 studies all time

What they study most

Cardiovascular Risk, Chronic Kidney Disease, Colitis, Ulcerative, Crohn's Disease, Diffuse Cutaneous Systemic Sclerosis, Inflammation, Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention, Lupus Erythematosus, Systemic, Lupus Nephritis, Moderately to Severely Active Crohn Disease, Primary Sjogren's Disease, Primary Sjogrens Disease

Studies at this site

• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Recruiting now
• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis — Recruiting now
• Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease — Recruiting now
• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus — Enrolling by invitation
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) — Running, not enrolling
• Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) — Running, not enrolling
• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Completed
• Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease — Running, not enrolling
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome — Running, not enrolling
• An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice — Stopped early